Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

Many pharma companies have begun shifting their R&D portfolios to the development of new cancer drugs. A pharma company recently announced a bold new cancer drug R&D portfolio strategy where the company will focus on early-stage cancers over late-stage (advanced) cancers for new drug development. This shift in focus goes against the standard target development paradigm where companies ...

Orphan drugs (ODs) for rare diseases (RDs) present pharma companies with the opportunity to address a substantial unmet medical need, with approximately 7,000 RDs and only about 5% having effective treatments. A large number of patients in the US are affected by these RDs (around 25-30 million people). The majority of RDs affect children. Also, RDs often translate into chronic and deteriorating ...

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...